| |
|
|
|
|
|
 |
| |
|
¸ÞÅ亼ÁÖ»ç500mg [Methocarbamol]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A06750101]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/5ml/¾ÚÇÃ(2006.02.01)(ÇöÀç¾à°¡)
\1,074 ¿ø/5ml/¾ÚÇÃ(2002.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
±Ù°ñ°Ý°è Áúȯ¿¡ ¼ö¹ÝÇÏ´Â µ¿Å뼺 ¿¬Ãà : ¿ä¹èÅëÁõ, °æ°ß¿ÏÁõÈıº, °ß°üÀýÁÖÀ§¿°, º¯Çü¼ºÃ´ÃßÁõ
|
| 1ÀÏ ÃÖ´ë Åõ¿©·® |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ : ¸ÞÅäÄ«¸£¹Ù¸ô·Î¼ 1ȸ 500§·À» ±ÙÀ° ¶Ç´Â Á¤¸ÆÁÖ»çÇÑ´Ù. 1ȸ 1g, 1ÀÏ ÃÑÅõ¿©·® 3gÀ» ÃʰúÇÏÁö ¾ÊÀ¸¸ç ¿¬¼ÓÀûÀ¸·Î 3ÀÏÀ» ÃʰúÇÏ¿© Åõ¿©ÇÏÁö ¾Ê´Â´Ù. ´Ü, µ¿ÅëÀÌ Áö¼Ó½Ã °æ¿ì¿¡ µû¶ó¼ 48½Ã°£ÈÄ ÁÖÀÇÇÏ¿© µ¿ÀϰúÁ¤À» ¹Ýº¹ÇÒ ¼ö ÀÖ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à ¶Ç´Â À¯»çÈÇÕ¹°(¸ÞÇÁ·Î¹Ù¸ÞÀÌÆ® µî)¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ½ÅÀå¾Ö ¶Ç´Â ½ÅÀå¾Ö°¡ ÀǽɵǴ ȯÀÚ
3) ÁßÁõÀÇ ±Ù¹«·ÂÁõ ȯÀÚ
4) È¥¼ö ¶Ç´Â ÀüÈ¥¼ö»óÅ ȯÀÚ
5) ³ú¼Õ»ó, °£Áú ¶Ç´Â °æ·ÃÀÇ º´·ÂÀÌ Àִ ȯÀÚ |
| ½ÅÁßÅõ¿© |
°£Àå¾Ö ȯÀÚ(Áõ»óÀ» ¾ÇȽÃų ¼ö ÀÖ´Ù.) |
| ÀÌ»ó¹ÝÀÀ |
1) °ú¹ÎÁõ : ¶§¶§·Î ¹ßÁø, µÎµå·¯±â, °¡·Á¿ò, µå¹°°Ô ¼ïÀ¯»çÁõ»ó µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
2) ¼øÈ¯±â°è : ¶§‹š·Î ¼¸Æ, Ç÷¾ÐÀúÇÏ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) Á¤½Å½Å°æ°è : ¶§‹š·Î Á¹À½, ¾îÁö·¯¿ò, ÈÖû°Å¸², ¿îµ¿½ÇÁ¶, µÎÅë, µÎÁß°¨, Á¹µµ, ½Ç½Å, µå¹°°Ô ½Ã·ÂºÒ¼±¸í µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â °¨·® ¶Ç´Â Åõ¿©ÁßÁö µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
4) ¼Òȱâ°è : ¶§¶§·Î ±¸¿ª¡¤±¸Åä, ½Ä¿åºÎÁø, °¡½¿¾²¸²¡¤À§Á¤Ã¼°¨¡¤À§ºÎºÒÄè°¨, ¼³»ç, º¯ºñ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) °¨°¢±â°è : ¶§¶§·Î ±Ý¼Ó¼ºÀÇ ¹Ì°¨À» ´À³¥ ¼ö ÀÖ´Ù.
6) ±âŸ : ¹ß¿, ºñÃæÇ÷ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
7) ÁÖ»çºÎÀ§ : ¶§¶§·Î µ¿Åë, °æ°á, µå¹°°Ô Ç÷Àü¼ºÁ¤¸Æ¿°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù(ÁÖ»çÁ¦¿¡ ÇÑÇÔ).
|
| »óÈ£ÀÛ¿ë |
1) ´ÙÀ½ ¾à¹°°úÀÇ º´¿ë ¶Ç´Â À½ÁÖ¿¡ ÀÇÇÏ¿© »óÈ£ÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖÀ¸¹Ç·Î ´Üµ¶Åõ¿©ÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷Çϳª ºÎµæÀÌÇÏ°Ô º´¿ëÇÏ´Â °æ¿ì¿¡´Â °¨·®ÇÏ´Â µî ÁÖÀÇÇÑ´Ù. : Æä³ëÄ¡¾ÆÁø°è ¾à¹°(Ŭ·Î¸£ÇÁ·Î¸¶Áø µî), ¹Ù¸£ºñÅ»°è ¾à¹° µîÀÇ ÁßÃ߽Űæ¾ïÁ¦Á¦, MAO ÀúÇØÁ¦
2) ¿°»êÅçÆä¸®¼Õ°ú º´¿ëÅõ¿©½Ã ½ÃÁ¶ÀýÀå¾Ö°¡ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù. |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Methocarbamol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The mechanism of action of methocarbamol in humans has not been established, but may be due to central nervous system depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.
|
| Pharmacology |
Methocarbamol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Methocarbamol is a central muscle relaxant for skeletal muscles, used to treat spasms. It is structurally related to guaifenesin. Methocarbamol's exact mechanism of causing skeletal muscle relaxation is unknown. It is thought to work centrally, perhaps by general depressant effects. It has no direct relaxant effects on striated muscle, nerve fibers, or the motor endplate. It will not directly relax contracted skeletal muscles. The drug has a secondary sedative effect.
|
| Protein Binding |
Methocarbamol¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Methocarbamol¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1.14-1.24 hours
|
| Absorption |
Methocarbamol¿¡ ´ëÇÑ Absorption Á¤º¸ Rapid. Onset of action is about 30 minutes after oral administration.
|
| Pharmacokinetics |
MethocarbamolÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ±ÙÀÌ¿ÏÈ¿°ú ¹ßÇö½Ã°£ : °æ±¸ : 30ºÐ À̳»
- ´ë»ç : °£´ë»ç
- ¹Ý°¨±â : 1-2 ½Ã°£
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : ¾à 2½Ã°£
- ¼Ò½Ç : ´ë»çü·Î¼ ½Å¹è¼³µÊ
|
| Biotransformation |
Methocarbamol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic.
|
| Toxicity |
Methocarbamol¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include blurred vision, coma, drowsiness, low blood pressure, nausea, and seizures.
|
| Drug Interactions |
Methocarbamol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Methocarbamol¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take without regard to meals.
|
| Description |
Methocarbamol¿¡ ´ëÇÑ Description Á¤º¸ A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)
|
| Drug Category |
Methocarbamol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Muscle Relaxants, Central
|
| Smiles String Canonical |
Methocarbamol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ COC1=CC=CC=C1OCC(O)COC(N)=O
|
| Smiles String Isomeric |
Methocarbamol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ COC1=CC=CC=C1OC[C@@H](O)COC(N)=O
|
| InChI Identifier |
Methocarbamol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)/f/h12H2
|
| Chemical IUPAC Name |
Methocarbamol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ [2-hydroxy-3-(2-methoxyphenoxy)propyl] carbamate
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-08-21
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|